Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721385 | 0.92 | MGLL (0.43) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL4405416 | 0.88 | MGLL (0.42) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL18356669 | 0.88 | MGLL (0.42) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL26519953 | 0.85 | MGLL (0.49) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL24621693 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL10018583 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL30259429 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL29869032 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL29608026 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB | |
| SCHEMBL29441383 | 0.85 | MGLL (0.55) | MGLLSMN1; SMN2HPGDHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | MGLL 4787/4885SMN1; SMN2 3931/4885HPGD 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.